Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Saurabh Dang

Interventional Pain Medicine Edgewater, NJ Medical Doctor

NPI 1619267374 CMS profile 1384164

20 Vela Way, Edgewater, NJ 07020

Open in the dashboard

General payments

$156,550

644 records reported · program years 2019–2025

Research payments

$1,315

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$99,139

2 holdings reported · through program year 2025

Research they led as principal investigator

$65,296 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Saurabh Dang of Edgewater, NJ is reported in the CMS Open Payments database as having received $156,550 across 644 general payments and $1,315 in research payments paid to them. Separately, studies naming them as principal investigator received $65,296 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $99,139 across 2 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,148 90
2024 General $17,222 98
2023 General $17,403 104
2022 General $18,185 85
2022 Research $1,315 1
2021 General $36,102 93
2020 General $35,341 88
2019 General $19,148 86
2025 Ownership $49,139 1
2024 Ownership $50,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Saurabh Dang
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Saurabh Dang were reported at $13,148. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Saurabh Dang Interventional Pain Medicine median Middle half National median
2019 $19,148 $684 $216–$2,079 $163
2020 $35,341 $382 $122–$1,109 $114
2021 $36,102 $552 $167–$1,554 $132
2022 $18,185 $605 $187–$1,924 $149
2023 $17,403 $671 $195–$1,915 $160
2024 $17,222 $684 $206–$1,837 $164
2025 $13,148 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $89,353 142 payments
  2. Medtronic, Inc. $31,573 115 payments
  3. Medtronic USA, Inc. $12,559 41 payments
  4. Abbott Laboratories $7,105 28 payments
  5. Saluda Medical Americas, Inc. $3,657 42 payments
  6. BIOTRONIK NRO, Inc. $2,138 48 payments
  7. Medtronic Vascular, Inc. $1,929 8 payments
  8. Nevro Corp. $1,266 24 payments
  9. Relievant Medsystems, Inc. $897 3 payments
  10. Flowonix Medical Incorporated $871 1 payment
  11. Other $5,203 192 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $86,463 52 payments
  2. Consulting Fee $31,887 17 payments
  3. Food and Beverage $27,600 539 payments
  4. Travel and Lodging $10,600 36 payments
Products named General payments · program years 2019–2025
  1. SPECTRA WAVEWRITER $17,953 18 payments
  2. WaveWriter Alpha Prime 16 $14,914 15 payments
  3. INTELLIS ADAPTIVESTIM $12,779 56 payments
  4. GENERAL PAIN MANAGEMENT $10,503 24 payments
  5. WAVEWRITER ALPHA Pain Management $10,111 4 payments
  6. General - Therapies $7,354 11 payments
  7. INTELLIS Spinal Cord Neurostimulation $6,715 23 payments
  8. WAVEWRITER ALPHA Pain Management $6,400 2 payments
  9. INTELLIS Spinal Cord Neurostimulation $5,705 19 payments
  10. Neuromodulation Dspsbls and Accs $4,912 2 payments
  11. Other $42,877 426 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Nevro Corp. $1,315 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

372

Median for Pain Management: 951

Drug cost

$13,827

Median for Pain Management: $26,034

Branded share of claims

30.9%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 12 $5,685
Movantik Naloxegol Oxalate Brand 12 $4,810
Oxycodone Hcl Generic 50 $857
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 68 $831
Pregabalin Generic 38 $445
Gabapentin Generic 47 $442
Cyclobenzaprine Hcl Generic 64 $262
Endocet Oxycodone Hcl/Acetaminophen Brand 11 $135
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $128
Tizanidine Hcl Generic 19 $111

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$72,721

Of which drugs: $566

Medicare patients

147

Average age 70

Services billed

635

91 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 41%
Depression 41%
Ischemic heart disease 34%
COPD 24%
Osteoporosis 19%
Chronic kidney disease 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 11 39 $30

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZTLido
$94 — —
Prialt
$79 — —
XTAMPZA
$29 — —
RELISTOR
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

645 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record